2014

Type 2 Diabetes Market Size, Share, Forecast and Analysis - Reach $38.8 Billion by 2019 New Market Research Report on Researchmoz.us

ALBANY, New York, September 25, 2013 /PRNewswire/ --

New Report Added in ResearchMoz Reports Database Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

ResearchMoz announces that it has published a new study Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019

Researchmoz.us added New Market Research Report which included in Diabetes Market Research Reports & Industry Analysis (http://www.researchmoz.us/diabetes-market-reports-29.html  ) Title of that Report "Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019 (http://www.researchmoz.us/type-2-diabetes-market-to-2019-a-shifting-treatment-algorithm-and-intensified-competition-expected-to-drive-growth-by-2019-report.html)" to its vast database.

Research has released its latest report for the pharmaceuticals industry, "Type 2 Diabetes Market to 2019 - A Shifting Treatment Algorithm and Intensified Competition Expected to Drive Growth by 2019". There is currently a large number of blood glucose-lowering drugs in the crowded type 2 diabetes market indicated for the treatment of chronically high blood glucose. The market is led by Lantus, which achieved global sales amounting to $6.4 billion in 2012. Over the forecast period from 2012 to 2019, the safer, more efficacious newer classes of drug (GLP-1 agonists, DPP-4 Inhibitors and SGLT-2 inhibitors) are expected to capture substantial market shares, largely replacing older classes such as sulfonylureas and thiazolidinediones.

Additionally, a variety of novel drugs belonging to these newer classes are due to enter the market, and are expected to offer a moderate improvement in terms of efficacy and safety. The price of these new therapies is expected to be high, but this is unlikely to hinder their uptake. As a result, as well as an overall increase in the prevalent population, GBI Research believes that the value of the global market has the potential to grow to reach $38.8 billion by 2019.

Scope

A brief introduction to type 2 diabetes, including the symptoms, pathogenesis, risk factors and diagnosis

In-depth analysis of major glucose-lowering drugs for type 2 diabetes, including analyses of their safety, efficacy, treatment patterns, strengths/weaknesses and overall commercial prospects. Includes a heat map comparing major drugs in terms of safety, efficacy and dosing parameters.

Comprehensive review of the pipeline for type 2 diabetes therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets.

Additional in-depth analysis of pipeline drug clinical trials by phase, molecule type, trial size, trial duration and program failure rate analyses for each molecule type and mechanism of action

Multi-scenario forecast data for the market up to 2019, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across key developed markets including the US, Japan, Germany, the UK, France, Italy and Spain

Discussion of the drivers and barriers for market growth

Reasons to Buy

Understand the many different types of type 2 diabetes therapies on the market, from the older, established classes of treatment to newer, moderately superior types of drug, and their positions in the treatment algorithm

Understand the strengths and weaknesses of each product

Understand the scope of the pipeline, including which molecule types and mechanisms of action are prominent

Observe trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for type 2 diabetes therapeutics

Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the type 2 diabetes therapeutics market.

TABLE OF CONTENT

1 Table of Contents 1

1.1 List of Tables 5

1.2 List of Figures 6

2 Executive Summary 7

2.1 A Highly Competitive and Growing Market 7

2.2 Strong Pipeline Containing a Diverse Set of Products 8

3 Introduction 9

3.1 Epidemiology 9

3.2 Symptoms 9

3.3 Etiology 10

3.4 Pathophysiology 10

3.5 Co-morbidities and Complications 11

3.6 Classification 12

3.7 Prognosis 13

3.8 Diagnosis 13

3.9 Assessing Treatment Effectiveness 15

3.10 Treatment Algorithm 15

3.10.1 The Role of Insulin in Type 2 Diabetes 17

3.10.2 Non-insulin Diabetic Drugs 18

3.10.3 Other Drugs 20

3.11 GBI Research Report Guidance 20

4 Key Marketed Products 21

4.1 DPP-4 Inhibitors 21

4.1.1 Januvia (sitagliptin) - Merck & Co 21

4.1.2 Tradjenta (linagliptin) - Boehringer Ingelheim 23

4.1.3 Onglyza (saxagliptin) - Bristol-Myers Squibb and AstraZeneca 24

4.1.4 Nesina (alogliptin) - Takeda 24

4.1.5 Galvus (vildagliptin) - Novartis 25

4.2 GLP-1 Agonists 26

4.2.1 Byetta and Bydureon (exenatide) - Bristol-Myers Squibb 26

4.2.2 Lyxumia (lixisenatide) - Sanofi 27

4.2.3 Victoza (liraglutide) - Novo Nordisk 28

4.3 Sulfonylureas 28

4.3.1 Glimepiride 28

4.3.2 Gliclazide 29

4.4 Thiazolidinediones 30

4.4.1 Actos (pioglitazone) - Takeda Pharmaceuticals Limited 30

4.4.2 Avandia (rosiglitazone) - GlaxoSmithKline 31

4.5 Other 32

4.5.1 Metformin 32

4.5.2 Lantus (insulin glargine) - Sanofi 33

4.5.3 Levemir (insulin detemir) - Novo Nordisk 34

4.5.4 Forxiga (dapagliflozin) - Bristol-Myers Squibb 35

4.6 Heat Map for Marketed Products 35

5 Pipeline for Type 2 Diabetes 39

5.1 Overall Pipeline 39

5.2 Therapeutic Classes 40

5.3 Rate of Attrition 42

5.3.1 Failure Rate by Molecule Type 42

5.3.2 Failure Rate by Therapeutic Class 44

5.4 Reasons for Failure of Developmental Programs 46

5.5 Clinical Trial Duration 46

5.5.1 Duration by Molecule Type 46

5.5.2 Duration by Therapeutic Class 47

5.6 Clinical Trial Size 48

5.6.1 Clinical Trial Size by Molecule Type 49

5.6.2 Clinical Trial Size by Therapeutic Class 51

5.7 Promising Drugs in the Pipeline 53

5.7.1 LY-2189265 (dulaglutide) - Eli Lilly 53

5.7.2 Albiglutide - GlaxoSmithKline 53

5.7.3 LC15-044 (gemigliptin) - LG Life Sciences 54

5.7.4 TAK-875 - Takeda 54

5.7.5 Ipragliflozin - Astellas Pharma 55

5.7.6 LX-4211 - Lexicon Pharmaceuticals 55

5.7.7 Imeglimin - Poxel SA 56

5.7.8 CCX-140-B - ChemoCentryx 56

5.7.9 Semaglutide - Novo Nordisk A/S 57

5.7.10 PC-DAC Exendin-4 - ConjuChem Biotechnologies 57

5.8 Heat Map for Pipeline Products 57

5.9 Conclusion 60

6 Market Forecast to 2019 62

6.1 Global Market 62

6.1.1 Treatment Usage Patterns 62

6.1.2 Market Size 63

6.2 US 64

6.2.1 Treatment Usage Patterns 64

6.2.2 Annual Cost of Therapy 65

6.2.3 Market Size 65

6.3 Top Five Countries of Europe 66

6.3.1 Treatment Usage Patterns 66

6.3.2 Annual Cost of Therapy 67

6.3.3 Market Size 68

6.4 Japan 69

6.4.1 Treatment Usage Patterns 69

6.4.2 Annual Cost of Therapy 70

6.4.3 Market Size 70

6.5 Drivers and Barriers 71

6.5.1 Drivers 71

6.5.2 Barriers 71

7 Deals and Strategic Consolidations 72

7.1 Licensing Deals 72

7.1.1 TransTech Pharma Enters into Licensing Agreement with Forest Laboratories 74

7.1.2 Xoma Enters into Licensing Agreement with Les Laboratoires Servier for Xoma 052 75

7.1.3 Zealand Pharma Enters into a Licensing and Collaboration Agreement with Boehringer Ingelheim 75

7.1.4 Exelixis Enters into Licensing Agreement with Bristol-Myers Squibb for XL475 75

7.1.5 Prosidion Limited Enters into a Licensing Agreement with Eli Lilly and Company 76

7.1.6 Metabolex Enters into Licensing Agreement with Sanofi 76

7.1.7 Wellstat Enters into a License Agreement with Sanofi 76

7.1.8 CureDM and Lankenau Institute Enter into a Licensing Agreement with Sanofi 76

7.1.9 Metabolex Enters into a Development and Licensing Agreement with Janssen Pharmaceuticals 76

7.1.10 Dainippon Sumitomo Pharma Enters into Licensing Agreement with Intercept Pharma for INT-747 77

7.1.11 Ipsen Enters into Licensing Agreement with F. Hoffmann-La Roche for BIM 51077 77

7.1.12 Glenmark Pharma Enters into Licensing Agreement with Merck KGaA 77

7.1.13 Euroscreen Enters into Licensing Agreement with Janssen Pharmaceuticals 77

7.1.14 Phenomix Enters into Licensing Agreement with Chiesi Farmaceutici 78

7.1.15 Otsuka Pharma Enters into Licensing Agreement with Kyowa Hakko Kirin for Saxagliptin 78

7.1.16 Nastech Pharma Enters into Licensing Agreement with Amylin Pharma 78

7.1.17 Emisphere Technologies Enters into a Licensing Agreement with Novo Nordisk 78

7.1.18 Array BioPharma Enters into a Licensing Agreement with Amgen 78

7.1.19 Theratechnologies Enters into a Licensing Agreement with OctoPlus 79

7.1.20 Diabetica Enters into a Licensing Agreement with Amylin 79

7.1.21 Celtic Therapeutics Enters into a Licensing Agreement with Bellus Health 79

7.1.22 Aradigm Enters into a Licensing Agreement with Novo Nordisk 79

7.1.23 Santarus Enters into a License Agreement with Shore Therapeutics 80

7.1.24 Depomed Enters into a Licensing Agreement with Boehringer Ingelheim 80

7.1.25 Depomed Enters into a Licensing Agreement with Merck 80

7.1.26 Depomed Enters into a Licensing Agreement with Teva 80

7.2 Co-development Deals 81

7.2.1 Eli Lilly Enters into a Co-development Agreement with Boehringer Ingelheim 82

7.2.2 AstraZeneca Enters into Co-development Agreement with Bristol-Myers Squibb 82

7.2.3 Metabolex Enters into a Co-development Agreement with Janssen Pharmaceuticals 83

7.2.4 Amylin Pharma Terminates Co-development Agreement with Eli Lilly for Exenatide 83

7.2.5 Isis Enters into a Collaboration Agreement with Janssen Pharmaceuticals 83

7.2.6 Neurocrine Biosciences Enters into a Collaboration Agreement with Boehringer Ingelheim 84

7.2.7 Intercept Pharma Enters into Co-development Agreement with Servier 84

7.2.8 Transition Therapeutics Enters into an Agreement with Eli Lilly 84

7.2.9 Ambrx Enters into a Co-Development Agreement with Bristol-Myers Squibb 84

7.2.10 Biocompatibles Enters into a Co-Development Agreement with AstraZeneca 85

8 Appendix 86

8.1 All Pipeline Drugs by Stage of Development 86

8.1.1 Discovery 86

8.1.2 Preclinical and IND-filed 88

8.1.3 Phase I 92

8.1.4 Phase II 95

8.1.5 Phase III and Pre-registration 98

8.1.6 Undisclosed 101

8.2 Market Forecasts to 2019 102

8.2.1 Global 102

8.2.2 US 102

8.2.3 UK 103

8.2.4 France 103

8.2.5 Germany 104

8.2.6 Italy 104

8.2.7 Spain 105

8.2.8 Japan 105

8.3 Market Definitions 106

8.4 Abbreviations 106

8.5 References for Heat Maps 108

8.6 References 111

8.7 Research Methodology 116

8.7.1 Coverage 116

8.7.2 Secondary Research 117

8.7.3 Primary Research 117

8.7.4 Therapeutic Landscape 117

8.7.5 Epidemiology-based Forecasting 118

8.7.6 Pipeline Analysis 120

8.7.7 Expert Panel Validation 120

8.7.8 Contact Us 120

Related Reports:

Craft Beer Market in the US 2012-2016:  New Analysts forecast the Craft Beer market in the US to grow at a CAGR of 17.46 percent over the period 2012-2016. One of the key factors contributing to this market growth is the changing consumer taste and preference for craft beer. The Craft Beer market in the US has also been witnessing an increase in canned craft beer production. However, lack of awareness about craft beer among consumers could pose a challenge to the growth of this market. The Craft Beer Market in the US 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Great Lakes and Plains regions, and the Western, Mid-south, Southeastern, South Central, and Northeastern regions of the US; it also covers the growth prospects of the market in the coming years. The report also includes a discussion of the key vendors operating in this market. Browse Complete Report with TOC@ http://www.researchmoz.us/craft-beer-market-in-the-us-2012-2016-report.html

###

Global SMB Web Analytics Market 2012-2016:  New study Business Process Management (BPM: Market Shares, Strategy, and Forecasts, Worldwide, 2012 to 2018. The 2012 study has 533 pages, 172 tables and figures. Worldwide markets are poised to achieve significant growth as people seek to control automated process better and interact with it in a more flexible manner.According to Susan Eustis, lead author of the WinterGreen Research team that prepared the study, "Cloud computing and smart devices represent the major forces impacting business process management (BPM) markets. As the enterprise managers work to implement apps that make automated process more responsive to the needs of customers, partners, suppliers, and distributors, people use business process management (BPM) as the tools to help workers.Browse Complete Report with TOC@ http://www.researchmoz.us/global-smb-web-analytics-market-2012-2016-report.html

###

Global Advanced Analytics Market 2012-2016 : Analysts forecast the Global Advanced Analytics market to grow at a CAGR of 13.62 percent over the period 2012-2016. One of the key factors contributing to this market growth is the growth of predictive analytics. The Global Advanced Analytics market has also been witnessing the emergence of advanced analytics in social gaming. However, the lack of expertise could pose a challenge to the growth of this market. The Global Advanced Analytics Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA and APAC regions; it also covers the Global Advanced Analytics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. Browse Complete Report With TOC@ http://www.researchmoz.us/global-advanced-analytics-market-2012-2016-report.html

###

Advanced Analytics in the Social Gaming Industry 2012 : Advanced gaming analytics help social gaming companies improve their understanding of game-related data and use this understanding to gain insights into consumer behavior. These insights also help companies deal with a varied range of areas that have significant potential to enhance gaming success. They also provide companies with a better understanding about why users quit a certain game, and help them find other players that are likely to abandon the game. Using these insights, gaming companies can develop retention strategies before players quit their game, and this in turn optimizes ad-generated interaction and in-game virtual goods sales. TechNavio's analysts expect the Advanced Analytics segment in the Social Gaming industry to grow rapidly over the period 2012-2016. The growth of the Advanced Analytics segment is driven by many factors. One of the major drivers is the need for enterprises to optimize consumer relationships. Advanced analytics provides an insight into the purchasing-related demand for various products. This insight is then used by marketers to formulate marketing strategies for greater sales visibility of their products and also to encourage increased consumer satisfaction. Browse Complete Report With TOC@ http://www.researchmoz.us/advanced-analytics-in-the-social-gaming-industry-2012-report.html

Browse Complete Report with TOC@ http://www.researchmoz.us/type-2-diabetes-market-to-2019-a-shifting-treatment-algorithm-and-intensified-competition-expected-to-drive-growth-by-2019-report.html

About Us

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

Contact
M/s. Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-997-4948

Email: sales@researchmoz.com
http://www.researchmoz.us/
http://www.researchmoz.blogspot.com/

SOURCE ResearchMoz




Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.